ADA Scientific Sessions 2026 Preview: 6 Trials to Know

The American Diabetes Association (ADA) 2026 Scientific Sessions are set to begin on Friday, June 5th, in New Orleans, Louisiana. The core of this year’s conference is the myriad GLP-1 therapies that have made substantial strides over recent months. The groundbreaking triple agonist retatrutide will be accompanied by CagriSema, survodutide, and elecoglipron as investigators showcase their efficacy in patients with diabetes and obesity.

The HCPLive editorial team will be on site at the conference for its entire duration, providing written coverage alongside key clinician interviews and insights. Keep an eye on our comprehensive coverage here – and in the meantime, check out what to expect from ADA 2026 below:

Trials to Watch

1. Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Obesity (TRIUMPH-1)

Presentation Time: 2:15 pm on Saturday, June 6

Presenter: Ania Jastreboff, MD, PhD

Eli Lilly’s investigational once-weekly triple agonist retatrutide has made substantial waves in the broader endocrinology sphere in recent months. The leading triple agonist in clinical trials, retatrutide works simultaneously to reduce appetite, boost fat burning, and increase expenditure of energy. TRIUMPH-1 was a phase 3 trial of retatrutide in patients with obesity and resulted in a staggering 70.3 pounds lost on average. The full data from this major study will be presented for the first time at ADA.

2. Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with T2D (TRANSCEND-T2D-1)

Presentation Time: 1:55pm on Saturday, June 6

Presenter: Harpreet Singh Bajaj, MD, MPH

Conducted simultaneously with TRIUMPH-1, the TRANSCEND-T2D-1 trial enrolled patients with type 2 diabetes (T2D) to receive retatrutide as an adjunct to diet and exercise. Ultimately, the patients displayed superior A1c reduction and weight loss compared to placebo, as well as improved cardiovascular risk factors like systolic blood pressure and cholesterol levels.

3. REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema

Presentation Time: REIMAGINE-1: 4:45pm on Sunday, June 7 | REIMAGINE-2: 5pm on Sunday, June 7 | REIMAGINE-3: 5:15pm on Sunday, June 7

Presenter: Vanita R. Aroda, MD (REIMAGINE-1); Akshay Jain, MD (REIMAGINE-2); Julio Rosenstock, MD (REIMAGINE-3)

CagriSema is a combination of cagrilintide and semaglutide for T2D management and was submitted to the US Food and Drug Administration (FDA) for weight loss at the end of 2025. Since then, the REIMAGINE 1, 2, and 3 trials have investigated the combination therapy alone, in comparison to its individual components, and as an add-on to basal insulin, respectively, in patients living with T2D. The results from each of these trials will be presented for the first time at ADA 2026.

4. Efficacy and Safety of Survodutide for the Treatment of Obesity in People without Diabetes: Results from SYNCHRONIZE-1

Presentation Time: 2:02pm on Sunday, June 7

Presenter: Carel le Roux, MBChB

Boehringer Ingelheim’s investigative glucagon/GLP-1 receptor dual agonist survodutide, granted Fast Track designation in 2021 and Breakthrough Therapy designation in 2024, led to substantial and sustained weight loss in patients with obesity compared with placebo. According to topline results, <85.1% of patients treated with survodutide compared to roughly 38.8% receiving placebo. Additionally, the majority of patients treated with survodutide saw a significant reduction in waist circumference, which investigators associate with visceral fat and cardiometabolic risk.

5. SOLSTICE: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus

Presentation Time: 3:35pm on Monday, June 8

Presenter: Vanita Aroda, MD

The SOLSTICE trial compared AZD5004 to placebo and semaglutide as an active comparator in patients with T2D mellitus and successfully reduced HbA1c levels from baseline by 26 weeks. Additionally, investigators recorded promising data regarding glycemic control and weight loss with AZD5004, leading AstraZeneca to advance the drug into phase 3 trials. The data from SOLSTICE and its companion study VISTA will be presented in full at ADA.

6. VISTA: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Participants Living with Obesity or Overweight with Comorbidity

Presentation Time: 3:15pm on Monday, June 8

Presenter: Melanie Davies, CBE

The companion to SOLSTICE, the VISTA phase 2b trial evaluated AZD5004 in patients with obesity compared to placebo. After 26 weeks of treatment, the investigative medication resulted in ≥5% body weight loss in a significant proportion of patients receiving AZD5004. Additional efficacy and safety data will be presented alongside SOLSTICE at the conference.